Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis

Article type: Research Article

Authors: Daifuku, Richard^a | Panacek, Edward A.^b | Haenftling, Katherine^a; | Swenson, Wendy K.^a | Prescott, Amanda W.^b | Johnson, John L.^b

Affiliations: [a] Cetus Corporation, Emeryville, CA, USA | [b] Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, USA

Note: [] Address reprint requests to Katherine Haenftling, Chiron, 1400 Fifty-third St., Emeryville, CA 94608, USA.

Abstract: MAB-T88 is a human monoclonal IgM antibody directed at the lipopolysaccharide of gram-negative bacteria. A protocol was designed to identify a group of septic patients with a very high likelihood of gram-negative bacteremia. All 6 patients entered in the protocol had a gram-negative source, and 4 of 6 had gram-negative bacteremia. In this patient population, MAB-T88 was shown to be safe with an effective half-life of 19.1 hours.

Keywords: gram-negative, IgM, lipopolysaccharide, monoclonal antibody, sepsis

DOI: 10.3233/HAB-1993-4107

Journal: Human Antibodies, vol. 4, no. 1, pp. 36-39, 1993